Simple Summary Immune checkpoint inhibitors (ICIs) aim to re-establish cancer immune control by modulating immune-inhibitory signaling pathways. ICIs are currently approved in breast cancer treatment act by blocking cell anti-PD-1/PD-L1 interactions. Nonetheless, as many mechanisms of immune escape can underlie the insurgence of cancer cells, most patients progress to ICIs, even when combined with chemotherapy. Multiplexed single-cell spatially resolved tissue analysis, by combining monoclonal antibodies with different reporters, can obtain precise single-cell epitope colocalization and thus allow to infer cellular functional states, while conserving their spatial coordinates. In this review, we highlight the potential of this technology in the context of breast cancer by selecting relevant prognostic and predictive markers through the lens of the cancer-immunity cycle. Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of many solid tumors. In breast cancer (BC), immunotherapy is currently approved in combination with chemotherapy, albeit only in triple-negative breast cancer. Unfortunately, most patients only derive limited benefit from ICIs, progressing either upfront or after an initial response. Therapeutics must engage with a heterogeneous network of complex stromal-cancer interactions that can fail at imposing cancer immune control in multiple domains, such as in the genomic, epigenomic, transcriptomic, proteomic, and metabolomic domains. To overcome these types of heterogeneous resistance phenotypes, several combinatorial strategies are underway. Still, they can be predicted to be effective only in the subgroups of patients in which those specific resistance mechanisms are effectively in place. As single biomarker predictive performances are necessarily suboptimal at capturing the complexity of this articulate network, precision immune-oncology calls for multi-omics tumor microenvironment profiling in order to identify unique predictive patterns and to proactively tailor combinatorial treatments. Multiplexed single-cell spatially resolved tissue analysis, through precise epitope colocalization, allows one to infer cellular functional states in view of their spatial organization. In this review, we discuss-through the lens of the cancer-immunity cycle-selected, established, and emerging markers that may be evaluated in multiplexed spatial protein panels to help identify prognostic and predictive patterns in BC.

Multiplexed In Situ Spatial Protein Profiling in the Pursuit of Precision Immuno-Oncology for Patients with Breast Cancer

Tosi, Anna;Rosato, Antonio;Guarneri, Valentina;Dieci, Maria Vittoria
2022

Abstract

Simple Summary Immune checkpoint inhibitors (ICIs) aim to re-establish cancer immune control by modulating immune-inhibitory signaling pathways. ICIs are currently approved in breast cancer treatment act by blocking cell anti-PD-1/PD-L1 interactions. Nonetheless, as many mechanisms of immune escape can underlie the insurgence of cancer cells, most patients progress to ICIs, even when combined with chemotherapy. Multiplexed single-cell spatially resolved tissue analysis, by combining monoclonal antibodies with different reporters, can obtain precise single-cell epitope colocalization and thus allow to infer cellular functional states, while conserving their spatial coordinates. In this review, we highlight the potential of this technology in the context of breast cancer by selecting relevant prognostic and predictive markers through the lens of the cancer-immunity cycle. Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of many solid tumors. In breast cancer (BC), immunotherapy is currently approved in combination with chemotherapy, albeit only in triple-negative breast cancer. Unfortunately, most patients only derive limited benefit from ICIs, progressing either upfront or after an initial response. Therapeutics must engage with a heterogeneous network of complex stromal-cancer interactions that can fail at imposing cancer immune control in multiple domains, such as in the genomic, epigenomic, transcriptomic, proteomic, and metabolomic domains. To overcome these types of heterogeneous resistance phenotypes, several combinatorial strategies are underway. Still, they can be predicted to be effective only in the subgroups of patients in which those specific resistance mechanisms are effectively in place. As single biomarker predictive performances are necessarily suboptimal at capturing the complexity of this articulate network, precision immune-oncology calls for multi-omics tumor microenvironment profiling in order to identify unique predictive patterns and to proactively tailor combinatorial treatments. Multiplexed single-cell spatially resolved tissue analysis, through precise epitope colocalization, allows one to infer cellular functional states in view of their spatial organization. In this review, we discuss-through the lens of the cancer-immunity cycle-selected, established, and emerging markers that may be evaluated in multiplexed spatial protein panels to help identify prognostic and predictive patterns in BC.
2022
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11577/3503394
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 6
  • OpenAlex ND
social impact